Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab in Cancer Cachexia
NCT05546476Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ponsegromab in cachexia, sponsored by Pfizer. Started Nov 2022; status: completed.
02
Drugs
ponsegromab
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT05546476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546476.